Follow
William Fraser Symmans
William Fraser Symmans
Professor of Pathology, University of Texas MD Anderson Cancer Center
Verified email at mdanderson.org
Title
Cited by
Cited by
Year
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
C Liedtke, C Mazouni, KR Hess, F André, A Tordai, JA Mejia, ...
Journal of clinical oncology 26 (8), 1275-1281, 2008
36192008
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ...
Annals of oncology 26 (2), 259-271, 2015
26462015
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier, CM Perou, WF Symmans, N Ibrahim, M Cristofanilli, ...
Clinical cancer research 11 (16), 5678-5685, 2005
25582005
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy
WF Symmans, F Peintinger, C Hatzis, R Rajan, H Kuerer, V Valero, ...
J clin Oncol 25 (28), 4414-4422, 2007
16452007
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial
JC Boughey, VJ Suman, EA Mittendorf, GM Ahrendt, LG Wilke, B Taback, ...
Jama 310 (14), 1455-1461, 2013
15302013
The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine
JS Ross, EA Slodkowska, WF Symmans, L Pusztai, PM Ravdin, ...
The oncologist 14 (4), 320-368, 2009
14522009
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
K Stemke-Hale, AM Gonzalez-Angulo, A Lluch, RM Neve, WL Kuo, ...
Cancer research 68 (15), 6084-6091, 2008
11872008
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
JS Ross, JA Fletcher, GP Linette, J Stec, E Clark, M Ayers, WF Symmans, ...
The oncologist 8 (4), 307-325, 2003
9572003
Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update.
KH Allison, MEH Hammond, M Dowsett, SE McKernin, LA Carey, ...
8562020
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
KR Hess, K Anderson, WF Symmans, V Valero, N Ibrahim, JA Mejia, ...
Journal of clinical oncology 24 (26), 4236-4244, 2006
8492006
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models
Nature biotechnology 28 (8), 827-838, 2010
8462010
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes
H Masuda, KA Baggerly, Y Wang, Y Zhang, AM Gonzalez-Angulo, ...
Clinical cancer research 19 (19), 5533-5540, 2013
8382013
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised …
S Loibl, J O'Shaughnessy, M Untch, WM Sikov, HS Rugo, MD McKee, ...
The lancet oncology 19 (4), 497-509, 2018
6802018
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
M Ayers, WF Symmans, J Stec, AI Damokosh, E Clark, K Hess, M Lecocke, ...
Journal of clinical oncology 22 (12), 2284-2293, 2004
6682004
An international Ki67 reproducibility study
MYC Polley, SCY Leung, LM McShane, D Gao, JC Hugh, ...
Journal of the National Cancer Institute 105 (24), 1897-1906, 2013
6652013
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer
L Gianni, M Zambetti, K Clark, J Baker, M Cronin, J Wu, G Mariani, ...
J Clin Oncol 23 (29), 7265-7277, 2005
6602005
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer
C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ...
Jama 305 (18), 1873-1881, 2011
6462011
Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype
WF Symmans, C Wei, R Gould, X Yu, Y Zhang, M Liu, A Walls, ...
Journal of Clinical Oncology 35 (10), 1049, 2017
6012017
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor …
AU Buzdar, V Valero, NK Ibrahim, D Francis, KR Broglio, RL Theriault, ...
Clinical Cancer Research 13 (1), 228-233, 2007
5962007
Adaptive randomization of veliparib–carboplatin treatment in breast cancer
HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ...
New England Journal of Medicine 375 (1), 23-34, 2016
5822016
The system can't perform the operation now. Try again later.
Articles 1–20